BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue26,35348,25713,608
Cost of Revenue2,2971,3681
Gross Profit24,05646,88913,607
Operating Expenses
Research Development61,00872,75851,796
Selling General and Administrative11,25313,0477,461
Non Recurring402528121
Total Operating Expenses---
Operating Income or Loss-48,607-39,444-45,771
Income from Continuing Operations
Total Other Income/Expenses Net-501,6255,580
Earnings Before Interest and Taxes-48,657-37,819-40,191
Interest Expense6,4875,2004,998
Income Before Tax-55,144-43,019-45,189
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-55,144-43,019-45,189
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-55,144-43,019-45,189
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-55,144-43,019-45,189